Navigation Links
Rigel To Focus On ITP, DLE And Dry Eye
Date:9/5/2013

s from a Phase 2 clinical study of R333 in DLE are expected in Q4 2013. 

Dry Eye

Dry eye disease is an inflammatory disease of the eye that affects more than 5 million Americans.  The disease targets the lacrimal (tear producing) glands of the eye and may be associated with other autoimmune conditions including Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis.  Rigel has developed a topical ophthalmic (eye drop) formulation of R348, a JAK and SYK inhibitor, aimed at reducing the inflammation responsible for the symptoms of this disease.  Results of a Phase 2 study of R348 in chronic dry eye are expected in Q2 2014.

About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders.  Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The company currently has five product candidates in clinical development: fostamatinib, an oral SYK inhibitor for ITP; R333, a topical JAK/SYK inhibitor for discoid lupus, and R348, a topical JAK/SYK inhibitor for dry eye – both in Phase 2 clinical trials; and two oncology product candidates in Phase 1 development with partners BerGenBio and Daiichi Sankyo.

This press release contains "forward-looking" statements, including, without limitation, statements related to development plans, the focus and direction of Rigel's resources, the timing of planned clinical trials and results, Rigel's ability to fund and manage its clinical programs in-house, Rigel's plans with respect to a reduction in force and restructuring charges associated with those reductions in force, and Rigel's ability to fund and maintain its current development pla
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rigel Announces First Quarter 2012 Financial Results
2. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
3. Rigel Announces Second Quarter 2012 Financial Results
4. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
5. Rigel to Present at UBS Global Life Sciences Conference
6. Rigel Announces Third Quarter 2012 Financial Results
7. Rigel to Present at Jefferies 2012 Global Healthcare Conference in London
8. Rigel to Present at BIO CEO & Investor Conference
9. Rigel Announces Participation at Two Investor Conferences
10. Rigel Announces Fourth Quarter and Year End 2012 Financial Results
11. Rigel Announces First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Australia , Sept. 18, 2014 Veterinary ... of Dr. Ashraf Hanna , M.D., Ph.D., and ... Board of Directors. Dr. Hanna is the Vice President ... Chief Financial Officer for the Genentech Foundation, while Dr. ... Head of Business Development and Licensing for Roche Pharma. ...
(Date:9/18/2014)... 18, 2014  Spring Bank Pharmaceuticals, Inc., a ... treatment of RNA viruses, today announced a research ... for animal testing of the Company,s lead compound, ... "Special Pathogens," against which currently there are no ... Spring Bank,s proprietary Small Molecule Nucleic Acid ...
(Date:9/18/2014)...   Auxilium Pharmaceuticals, Inc. (NASDAQ: ... announced the first presentation of positive safety and ... Investigation of Collagenase Optimizing the Resolution of Dupuytrens) ... histolyticum (CCH) for the treatment of two Dupuytren,s ... the study examined expanded flexibility with timing of ...
Breaking Medicine Technology:Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 2Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 3Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 4Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 5Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 6Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 7
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, ... common antidepressant can quickly alter the way brain cells communicate ... online Sept. 18 in Current Biology , are ... prescribed antidepressants. Experts said the hope is to eventually be ... benefit from a drug -- and which people would fare ...
(Date:9/18/2014)... true: exercise is good for you. But new research ... have an added benefit for cancer patients undergoing chemotherapy. ... melanoma, found that combining exercise with chemotherapy shrunk tumors ... associate professor in the School of Nursing and director ... was the senior author on the study, which appears ...
(Date:9/18/2014)... Texas (PRWEB) September 19, 2014 ... Inside the Neighborhood Mission (Misión Barrio Adentro), ... of the healthcare system (see Section 6.1.3.). ... billion) in an Autonomous Service of Pharmaceutical ... production plant, which provides medicines at a ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Thousands of ... be recognizing their shared fundraising impact on 127 member ... 25. , The first-ever Dance Marathon Day will officially ... million projected to be raised by college and high ... Hospital. Donations generated through Dance Marathon campus programs help ...
(Date:9/18/2014)... 18, 2014 Ben Quirk, CEO of ... Jr. Leadership Award by the Savannah Science Seminar in ... wellness throughout the nation and especially in Savannah. , ... said Ben. “The Savannah Science Seminar is an amazing ... multiple generations have gone through the program,” he added. ...
Breaking Medicine News(10 mins):Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2
... arms to snip away tumors , TUESDAY, Dec. 18 ... promise in the removal of cancer involving the tonsils, ... University of Pennsylvania, the transoral robotic surgery (TORS) system ... with an endoscope, an optical instrument with two video ...
... in the December issue of The Journal of the ... cancer operations in 80-year-olds are considerably worse than reported ... lead to unrealistic expectations about the safety of these ... patients and their physicians may have difficulty accurately assessing ...
... Calif., Dec. 18 BioMarin,Pharmaceutical Inc. (Nasdaq and ... Canadian rights for tetrahydrobiopterin (BH4), including,Kuvan(TM) (sapropterin dihydrochloride), ... Germany. Kuvan is an oral small molecule for ... Merck,Serono. Based on published literature, there are approximately ...
... 18 Art Mellor is one of,more than 400,000 ... from,Multiple Sclerosis (MS). It,s, a debilitating disease that causes,paralysis, ... no wonder that Mellor, the founder of the Accelerated,Cure ... and more,interested in raising the funds he needs to ...
... Southwestern Medical Center researchers have found that the existing body ... of obese patients at risk of cardiovascular disease. , ... Surgery for Obesity and Related Diseases, is among ... index (BMI) and cardiovascular disease as it relates to bariatric ...
... and Implantability Characteristics, MINNEAPOLIS, Dec. 18 ... manufacturer and marketer of state-of-the-art cardiac,surgery products ... Drug,Administration (FDA) approval for the ATS Open ... http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ), The ATS AP360 heart ...
Cached Medicine News:Health News:Robotic Surgery Treats Tonsil Cancer 2Health News:Study finds outcomes of high-risk cancer operations in 80-year-olds worse than reported 2Health News:BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono 2Health News:BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono 3Health News:BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono 4Health News:This Holiday Season Some Dream of a White Christmas - The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 2Health News:This Holiday Season Some Dream of a White Christmas - The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 3Health News:BMI criteria for obesity surgery should be lowered, UT Southwestern researchers suggest 2Health News:ATS Medical Receives FDA Approval for AP360 Mechanical Heart Valve 2Health News:ATS Medical Receives FDA Approval for AP360 Mechanical Heart Valve 3
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
... Cobalt Binding (ACB®) Test is a clinical ... (IMA®) by measuring the cobalt binding capacity ... First identified in the early 1990s, IMA ... contact with ischemic tissue in the heart. ...
Inquire...
Medicine Products: